Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Pharma
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
If approved by the FDA, BMS' Opdivo-Yervoy combo will go toe to toe with Roche's and AstraZeneca's immunotherapies in first-line liver cancer.
Angus Liu
Mar 20, 2024 10:18am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
BMS shows I-O duo's power in first-line colorectal cancer
Jan 20, 2024 10:00am
Lynparza fails to improve on Keytruda in first-line lung cancer
Dec 7, 2023 9:21am
BMS buys Mirati for up to $5.8B as I-O giant branches out
Oct 9, 2023 3:29am